It is an ugly fact that a significant amount of the world's population will contract SARS-CoV 
Introduction
In December 2019, several unidentified pneumonia cases occurred in Wuhan, China. On 30 January 2020, this led the World Health Organization (WHO) to declare a public health emergency of international concern. On 12 March 2020, the WHO declared the outbreak of the 2019 novel coronavirus, a global pandemic [1] [2] [3] . The WHO suggested the official name for the disease from this virus as the coronavirus disease 2019 . The Coronaviridae Study Group of the International Committee on Taxonomy of Viruses proposed the name of the virus as 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-II)', designated by its phylogeny and taxonomy [4] . Up to 4 April 2020, there are registered 1,117,942 confirmed cases and 59,201 deaths worldwide There are connections between age, diet, nutrients, and immunity in the elders [37] . The clinical or subclinical micronutrient deficiency is common in older adults, which contributes to several agerelated diseases and decreased immune functions [38, 39] . This prevalence is probably the consequence of the low appetite and the nature of little diversification of their dietary patterns in the elders. The nutritional assessment and proper management are, therefore, essential to determine the risk of infection, the illness course, and the outcome of COVID-19 in older adults [25] .
Microbiota
The diverse intestinal microbiota shapes the immune system and promotes the host well-being [40, 41] . The respiratory tract microbiota also influences the host immune responses to the virus [42] .
While the immune responses to viral infection determine the efficacy of a vaccine, the disrupted gut microbiota contribute to vaccine failures and other inflammatory conditions [43] . The acute respiratory viral infections disrupt the host-microbiota interactions and create the intestinal dysbiosis with the post-viral immune responses, that contribute to pneumonia development by the secondary bacterial infection [44] . The healthy, diverse intestinal and respiratory tract microbiota is then another critical determinant for the clinical courses of COVID-19 [42, 45] .
Interferons (IFNs) are the first line of immune defense against viral infection, particularly the type I IFNs and the type III IFNs, or IFN-λs [46] . Despite the preliminary understanding of their roles, IFNλs are probably the critical antiviral cytokines in the respiratory epithelial surfaces during the early stages of viral infection. While the type I IFN signaling during acute viral infection increase the proinflammatory responses, their signaling in the persistent infection modulates the counter-regulatory immune responses [47, 48] . Some gut microbiomes mediate the IFN responses to viral infection supplementation needs to start before the onset of respiratory tract infection. However, there is inconclusive evidence regarding the underlying mechanisms of vitamin D deficiency and viral disease development [66] . The potential mechanisms include the antiviral immune induction, the modulation of immunoregulatory defense, induction of autophagy and apoptosis, and genetic or epigenetic regulation [66] . Furthermore, the risk of viral infections can be reduced by vitamin D. The related mechanisms comprised of stimulation of defensins and cathelicidins that can decrease the replication of virus and increase levels of anti-inflammatory cytokines, as well as decreasing concentrations of pro-inflammatory cytokines that induce inflammation-related pneumonia [67] . Supportive data for the effective role of vitamin D in decreasing risk of COVID-19 could be highlighted by increased case-fatality rates with chronic disease comorbidity and age, in which lower concentrations of 25(OH)D have been reported. Vitamin D deficiency is globally prevalent, particularly in the elders [68] . Over half of the hospitalized elders and nursing home residents in the U.S. had vitamin D deficiency [69, 70] . This high prevalence probably contributes to the first outbreak COVID-19 during winter and the high mortality rate in older adults [71] [72] [73] [74] . While the natural source of vitamin D is from sunlight exposure, some dietary sources can provide a certain amount of vitamin D, including the fortified cereals and milk. However, for people at risk of COVID-19, the goal should be to raise the concentrations of 25(OH)D above 40-60 ng/ml (100-150 nmol/l) by considering taking expression, antibody production, and the enhanced functions of neutrophils, natural killer cells, monocytes or macrophages, T cells, and B cells [79, 80] .
Vitamin C
Vitamin C deficiency is associated with pneumonia in several pieces of literature in the early days [81, 82] . The immune-modulating effects in respiratory infection of vitamin C are also welldocumented [83] [84] [85] [86] . Nevertheless, the supporting evidence of vitamin C supplementation in the prevention and treatment of acute respiratory diseases are inconclusive [87] [88] [89] [90] . In alignment with the evidence of other micronutrients, the supplementation could benefit the vitamin C deficient individual but not in the healthy subjects [87, 88] . Moreover, it has been reported that megadoses administration of Vitamin C before or after the appearance of flu symptoms could prevent and relieve the flu symptoms in the test population regarding the control group [83, 86, 91, 92] . Based on 31 study comparisons with 9745 common cold episodes, it has been revealed that the regular supplementation of Vitamin C had a modest but consistent effect in decreasing the duration of common cold symptoms [89, 90] . Furthermore, five trials with 598 participants showed that vitamin C decreased the risk of common cold without any adverse effects [93] . Vitamin C supplementation is thus the sensible option to prevent and support the immune responses in the micronutrient-deficit individual at risk for COVID-19.
Selenium
As the integral part of several selenoproteins, including the glutathione peroxidases and thioredoxin reductases, selenium has a critical role in the defense against viral infection through its antioxidant, redox signaling, and redox homeostatic contributions [94] . Selenium deficiency is associated with increased pathogenicity of several virus infections [95] [96] [97] . In the deficient state, the selenium supplementation is helpful for the prevention and treatment of viral infections [97] [98] [99] [100] . Recently, it has been reported that a mild strain of influenza virus, also shows increased virulence in seleniumdeficient mice. Increased virulence is related to several modifications in the viral genome [95, 101] .
Furthermore, the immune response, such as proinflammatory chemokines, can be increased in J o u r n a l P r e -p r o o f Journal Pre-proof selenium-deficient mice. Moreover, the mRNA expression of macrophage inflammatory protein-1α and -1β, monocyte chemotactic protein-1, and RANTES (regulated upon activation, normal T cell expressed and secreted) were changed in selenium-deficient mice. The mRNA levels of cytokine were also modified in the selenium-deficient mice. IL-4, IL-5, IL-10, and IL-13 were increased, whereas γ-interferon and Interleukin (IL)-2 were decreased, which suggests a modification toward a pattern of T-helper-2-like in the Se-deficient mice regarding the pattern of T-helper-1-like in the Se-adequate mice [95] . Therefore, selenium intake differentially affects numerous types of immune responses and related mechanisms, revealing an effective role of selenium-supplementation in viral diseases.
Zinc
Zinc is an essential micronutrient with the crucial contributions to most enzymatic functions and the transcription regulations in the human body [30, 59] . Zinc is essential for normal function and development of cells regulating nonspecific immunity, including natural killer cells and neutrophils.
Zinc is the main structural component of around 750 zinc-finger transcription factors [102] . The deficiency of zinc also modifies the development of acquired immunity by limiting both the certain and outgrowth functions of T lymphocytes, including the production and activation of Th1 cytokine [103] . The function of macrophage also is adversely affected by the deficiency of zinc through the dysregulation of cytokine production, intracellular killing, and phagocytosis [103] . Zinc deficiency is surprisingly common in modern-day lifestyle [104] . Zinc deficiency impairs the antiviral immunity, particularly to herpes simplex, common cold, herpes simplex virus, hepatitis C, and the human immunodeficiency virus (HIV) [104, 105] . A meta-analysis of oral zinc supplementation studies suggested beneficial effects on the shortened of symptoms and duration of common cold infection [106] [107] [108] . Zinc supplementation was also helpful against hepatitis C virus infection through the induction of metallothionein expressions [109, 110] . Moreover, research has shown that zinc has antiviral effects; it improves immune responses and suppresses viral replication. Therefore, the consumption of up to 50 mg zinc per day may provide a protective role against the COVID-19 pandemic, likely by improving the host's resistance against viral infection [102] . However, these studies did not account for the underlying zinc status in the studied participants. 
Potential therapeutic options for COVID-19
There is yet no specific treatment for COVID-19. 
Antiviral medications and herbs
The antiviral medications target several components of the SARS-CoV-II lifecycle. These molecular targets include the viral entry into the host cells, the viral RNA synthesis, and the viral replication [112] . There are high sequence similarities in the genomes of SARS-CoV-II, SARSCoV, and MERS-CoV. It is possible for the shared effectiveness of the previously approved medications in these conditions for the treatment of COVID-19.
The blockages of the virus entry into the host cells

Chloroquine and hydroxychloroquine
These viral entry blockages include chloroquine, hydroxychloroquine umifenovir, and interferon [112] . A cell line study reported that chloroquine significantly decreased the human coronavirus-229E replication at a lower concentration than the clinical dosage [113] . A systematic review suggested the rationale, pre-clinical supporting evidence of the effectiveness against SARS-CoV-II, and the clinical J o u r n a l P r e -p r o o f Journal Pre-proof safety profiles, that justify future clinical research of chloroquine and hydroxychloroquine in patients with COVID-19 [114] .
There are currently several clinical trials of chloroquine for COVID-19, either as monotherapy or in combination with other medications such as azithromycin [112] . A non-randomized clinical trial reported the reduction of the viral load from the hydroxychloroquine-azithromycin combination in twenty COVID-19 patients but failed to report the critical clinical outcomes, including death [115] .
Chloroquine and hydroxychloroquine are the immunomodulatory drugs with potential antiviral effects. However, there are some long-known clinical side-effects and interactions with other medications. It is still premature to conclude the role of chloroquine and hydroxychloroquine in COVID-19, while several clinical trials are on their ways [116] .
The transmembrane protease, serine 2 (TMPRSS2) inhibitor
SARS-CoV -II enters the target cells through the angiotensin-converting enzyme 2 (ACE2) receptor
and the transmembrane protease, serine 2 (TMPRSS2). The TMPRSS2 inhibitors block the cellular entry of the SARS-CoV-II virus through the downregulated priming of the SARS-CoV-II spike protein [117, 118] . There is a known TMPRRSS2 inhibitor in the market, i.e., camostat mesylate. The machine learning algorithms on this entry pathway revealed some other mechanistic possibilities, including the Janus-associated kinase inhibitors through baricitinib, ruiolitinib, and imatinib [119, 120] . Some of these drugs are currently on the clinical trials for COVID-19.
The inhibitors of viral RNA synthesis
Remdesivir
The medications that inhibit viral RNA synthesis include remdesivir, favipiravir, and ribavirin.
Remdesivir is a novel nucleotide analog with the broad-spectrum antiviral activities against the singlestranded RNA viruses, including the Ebola virus, Marburg virus, respiratory syncytial virus, Junin virus, Lassa fever virus, Nipah virus, Hendra virus, and the coronaviruses [121] [122] [123] [124] . Remdesivir inhibits the RNA-dependent RNA polymerase, which crucially replicates copies of viral RNA in the host cells. The animal models and cell line studies suggested the effectiveness of remdesivir to J o u r n a l P r e -p r o o f Journal Pre-proof selectively inhibit the infection and pathology of MERS-CoV and SARS-CoV-II [125, 126] . While the proofreading exoribonuclease hampers the effects of most nucleotide-base antiviral treatment, remdesivir inhibits coronavirus with the intact proofreading, thus renders its superior antiviral efficacy [127] . The experimental treatment of intravenous remdesivir in the first COVID-19 patient in the U.S.
showed an impressive response [128] . There is a current randomized, placebo-controlled, doubleblind, multicenter, phase III clinical trial to determine the efficacy and safety of remdesivir in COVID-19 [129] .
Favipiravir
Favilavir is a guanine analog with the broad-spectrum antiviral activities through its selective inhibition of viral RNA-dependent RNA polymerase [130] . Favilavir has efficacy against various RNA viruses, including influenza, ebola, yellow fever, chikungunya, norovirus, and enterovirus [131, 132] . A recent cell line study suggested its efficacy against the SARS-CoV-II [133] . While it got the approval for novel influenza treatment, favipiravir is currently on the clinical trials for COVID-19 treatment by the National Infectious Diseases Scientific Science Research Center and the Shenzhen Third People's Hospital [134] . The preliminary results in eighty patients reported the superior efficacy of favipiravir than the lopinavir/ritonavir combination without the significant adverse reactions [135, 136] .
The viral replication inhibitors
The lopinavir-ritonavir combination
The medications that block the virus replication include lopinavir-ritonavir combination and darunavir-cobicistat combination. The lopinavir-ritonavir combination is a fixed-dose medication for the prevention and treatment of HIV infection [137] . The cytochrome P450 inhibitory effects of ritonavir prolonged the half-life of Lopinavir and extended its protease inhibitory action on the HIV replications. The in-vitro studies suggested that the lopinavir/ritonavir combination can inhibit coronavirus replication. 
Other potential therapeutic options
The human convalescent plasma
The human convalescent plasma from the recovered patients can be another option for COVID-19 management [158, 159] . The passive immunoglobulin-containing plasma can provide immediate immunity to the susceptible individual. There is a long history of this passive antibody treatment in various infective diseases beyond the era of antimicrobial development [160, 161] . A meta-analysis suggested the beneficial role of early administration of convalescent plasma on the mortality reduction during influenza epidermic in 1918 [159] . There is no report of serious adverse effects of the treatment up to now. The convalescent plasma from the patients who have recovered from the viral infection is thus another rational option for COVID-19 management [160, 161] .
The anticipating options
The monoclonal antibodies
The monoclonal antibodies are the well-recognized passive immunotherapeutic options in many diseases. This human-made antibody can specifically bind to the designated target, thus involves in its molecular mechanisms and provides the desirable effects, which can either inhibit or enhance those molecular pathways [162] . [163, 164] . These clinical trials include the monoclonal antibodies that target the pathogenic and pathophysiologic processes of COVID-19. These trials comprise the tocilizumab, which targets the interleukin-6 receptor and possibly mediates the SARSCoV II-mediated inflammation and modulates the cytokine storms, and several neutralized monoclonal antibodies targeting the SARS-CoV and MERS-CoV molecular mechanism [163, 165] .
Vaccines
Several companies and research groups initiate the development of potential vaccines for COVID-19.
These companies include Pfizer, GlaxoSmithKline, Johnson & Johnson, and many others. However, these trials are still in their early stages and require a certain period until their potential clinical launches. This anticipating option will not come soon [166] [167] [168] .
Concluding remarks
It is a great tragedy for the ugly fact that a lot of world population will contract SARS-CoV infection. J o u r n a l P r e -p r o o f
